Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Exclusion Criteria

• •Subjects unable to review and sign informed consent form
• •Females who are pregnant or breastfeeding, and males and females who cannot comply with requirements to avoid fathering a child or becoming pregnant
• •Subjects with known diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C; viral testing is not required; subjects with a history of Hepatitis B and/or C are allowed on trial if the virus is undetected at the time of enrollment
• •Subjects with inadequate liver (alanine aminotransferase \[ALT\]/serum glutamate pyruvate transaminase \[SGPT\] above 4 X upper limit of normal \[ULN\] or direct bilirubin 4 X ULN AND the lab abnormalities are felt to be due to underlying liver dysfunction)
• •Subjects with end stage renal function (creatinine clearance \[CrCl\] \< 15 mL/min or glomerular filtration rate \[GFR\] \<15 mL/min) regardless of whether hemodialysis is required
• •Subjects with clinically serious infections requiring ongoing antibiotic therapy
• •Subjects requiring therapeutic doses of anticoagulation or anti-platelet therapies (aspirin above 81 mg daily, Plavix or similar agents) AND platelet counts are below 50,000 on two different laboratory evaluations, separated by minimum of two weeks
• •Taking investigational or commercial agents or therapies with the intent to treat the subject's malignancy other than those therapies permitted
• •Subjects with invasive malignancy over the previous 2 years except treated early stage carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix, and completely resected papillary thyroid and follicular thyroid cancers
• •Previous allergic reactions to janus kinase (JAK) inhibitors or excipients
• •Prior therapy with ruxolitinib or other JAK inhibitors
• •Subjects who have had major surgery within 4 weeks prior to entering the study
• •Subjects who are anticipated to receive a transplant within the first 6 months of treatment on trial